...
首页> 外文期刊>British Journal of Haematology >LPL protein in Chronic Lymphocytic Leukaemia have different origins in Mutated and Unmutated patients. Advances for a new prognostic marker in CLL
【24h】

LPL protein in Chronic Lymphocytic Leukaemia have different origins in Mutated and Unmutated patients. Advances for a new prognostic marker in CLL

机译:慢性淋巴细胞白血病中的LPL蛋白在突变和未经化患者中具有不同的起源。 CLL中新预后标志物的进展

获取原文
获取原文并翻译 | 示例
           

摘要

Summary Lipoprotein lipase ( LPL ) mRNA expression in chronic lymphocytic leukaemia (CLL) is associated with an unmutated immunoglobulin profile and poor clinical outcome. We evaluated the subcellular localization of LPL protein in CLL cells that did or did not express LPL mRNA. Our results show that LPL protein is differently located in CLL cells depending on whether it is incorporated from the extracellular medium in mutated CLL or generated de novo by leukaemic cells of unmutated patients. The specific quantification of endogenous LPL protein correlates with mRNA expression levels and mutational IGHV status, suggesting LPL protein as a possible reliable prognostic marker in CLL.
机译:发明内容脂蛋白脂肪酶(LPL)mRNA在慢性淋巴细胞白血病(CLL)中的表达与未传养的免疫球蛋白型和临床结果不良有关。 我们在CLL细胞中评估了LPL蛋白的亚细胞定位,所述CLL细胞具有或未表达LPL mRNA。 我们的结果表明,LPL蛋白在CLL细胞中不同于CLL细胞,这取决于是否掺入突变的CLL中的细胞外培养基或通过未经传染患者的白血病细胞产生的DE Novo。 内源性LPL蛋白的特异性定量与mRNA表达水平和突变IGHV状态相关,表明LPL蛋白是CLL中可能的可靠预后标记。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号